abt-122
mAbexperimentalMulti-specific
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2013 (NCT01853033)
Timeline
Indications
Mechanism of action
- TNF-alphaImmunity, passive
TNF immunity, passive
- Interleukin 17AImmunity, passive
IL17A immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Also known as
- abt-122
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02429895 | Phase 2 | Oct 1, 2015 | AbbVie |
| NCT02349451 | Phase 2 | Apr 1, 2015 | AbbVie |
| NCT02433340 | Phase 2 | Apr 1, 2015 | AbbVie |
| NCT02141997 | Phase 2 | Jul 1, 2014 | AbbVie |
| NCT01853033 | Phase 1 | Jul 1, 2013 | AbbVie |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 5 | 5 | 2 | 2013 |
1 organizations
Page 1 / 1